An Alzheimer's Breakthrough
Rapid improvement in Alzheimer's, beginning within minutes of administration of the first dose of anti-TNF treatment, is a commonplace occurrence at the INR. Documentation and explanation of the physiologic basis for these unique treatment results has been made in a series of landmark scientific articles from the INR. The videos present on this website document the responses of actual INR patients to initiation and maintenance of anti-TNF treatment. Read more inside.
Frequently Asked Questions
Q: How long has the INR been using anti-TNF to treat Alzheimer's disease? A: The INR has more than seven years experience using its patented anti-TNF treatment for AD. The INR etanercept for Alzheimer's clinical trial was begun in 2004. Q: What is TNF? TNF is an immune signaling molecule that initiates and amplifies the inflammatory response in the human body. Q: How does etanercept work? Etanercept binds circulating TNF and thereby neutralizes the adverse effects of excess TNF.
Stroke Recovery
The INR has made a stunning discovery: that the neurological status of patients following stroke, even years after the acute event, may rapidly improve following the use of the INR’s patented local anti-TNF treatment (see www.strokebreakthrough.com for further detailed information). The INR's published results, and the subsequent clinical experience of INR physicians, suggest that excess TNF plays an important role in post-stroke chronic disability and establish the promise that the INR’s patented anti-TNF treatment presents for stroke recovery and stroke rehabilitation. Please call the INR in Los Angeles at (310) 824-6199 for further information